CoChat

Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer’s disease: metabolic basis for dementia

Open access

The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.

Abstract

Impairment of brain-glucose uptake and brain-copper regulation occurs in Alzheimer’s disease (AD). Here we sought to further elucidate the processes that cause neurodegeneration in AD by measuring levels of metabolites and metals in brain regions that undergo different degrees of damage. We employed mass spectrometry (MS) to measure metabolites and metals in seven post-mortem brain regions of nine AD patients and nine controls, and plasma-glucose and plasma-copper levels in an ante-mortem case-control study. Glucose, sorbitol and fructose were markedly elevated in all AD brain regions, whereas copper was correspondingly deficient throughout (all P < 0.0001). In the ante-mortem case-control study, by contrast, plasma-glucose and plasma-copper levels did not differ between patients and controls. There were pervasive defects in regulation of glucose and copper in AD brain but no evidence for corresponding systemic abnormalities in plasma. Elevation of brain glucose and deficient brain copper potentially contribute to the pathogenesis of neurodegeneration in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep27524

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Log2-transformed concentrations of glucose, sorbitol and fructose in post-mortem tissue from seven brain regions of nine patients with AD and nine controls. Individual values are shown for each region. At the right-hand side are detailed the identity, sex, age, brain-weight, and PMD of each participant, along with the histopathological diagnosis. One control (Case 15: F76, brain wt 1094 g; black squares) with higher metabolite concentrations than other controls had preclinical AD (Braak Stage II).
Figure 1 Log2-transformed concentrations of glucose, sorbitol and fructose in post-mortem tissue from seven brain regions of nine patients with AD and nine controls. Individual values are shown for each region. At the right-hand side are detailed the identity, sex, age, brain-weight, and PMD of each participant, along with the histopathological diagnosis. One control (Case 15: F76, brain wt 1094 g; black squares) with higher metabolite concentrations than other controls had preclinical AD (Braak Stage II).CC BY · PubMed Central
Figure 2 Probability density distributions of fold-changes from controls to cases in glucose, sorbitol and fructose measured in brain tissue from (a) each of seven brain regions from patients with AD (n = 9) and controls (n = 9), and (b) whole brain homogenates from diabetic (n = 7) and control (n = 7) rats. Distributions were derived by Bayesian modeling and illustrate the plausible ranges (posterior distributions) of inferred fold changes for each region and metabolite. This analysis complements the results of a mixed-effects model assessment of the fold-change between AD cases and controls for measurements of metabolites in each brain region. Posterior means (solid lines) and 95% credible intervals (dashed lines) are shown, along with the ‘no fold change’ value (solid black line). (b) Shown are results of an equivalent simulation of data from a metabolomic study of ex-vivo whole-brain tissue from diabetic rats and controls. Data were log2-transformed before analysis.
Figure 2 Probability density distributions of fold-changes from controls to cases in glucose, sorbitol and fructose measured in brain tissue from (a) each of seven brain regions from patients with AD (n = 9) and controls (n = 9), and (b) whole brain homogenates from diabetic (n = 7) and control (n = 7) rats. Distributions were derived by Bayesian modeling and illustrate the plausible ranges (posterior distributions) of inferred fold changes for each region and metabolite. This analysis complements the results of a mixed-effects model assessment of the fold-change between AD cases and controls for measurements of metabolites in each brain region. Posterior means (solid lines) and 95% credible intervals (dashed lines) are shown, along with the ‘no fold change’ value (solid black line). (b) Shown are results of an equivalent simulation of data from a metabolomic study of ex-vivo whole-brain tissue from diabetic rats and controls. Data were log2-transformed before analysis.CC BY · PubMed Central
Figure 3 Regional brain glucose (upper panel) and brain copper (μmol/dry kg; lower panel) levels in patients with AD (n = 7–9/region; red) and controls (n = 7–9; black). Overall mean ( ± 95% CI; Confidence Interval) wet-weight/dry-weight ratio was 5.6 (5.4–5.8). Overall mean brain-glucose levels were higher (P = 9.7 × 10−13) and brain copper values lower (P = 1.6 × 10−8) in cases than controls. Mean brain copper in AD trended lower in every region: CB (P < 0.0001); MCx (P = 0.021); SCx (P = 0.027); CG (P = 0.0079); MTG (P = 0.013); ENT (P = 0.0046); and HP (P = 0.070); and there was modest evidence that overall brain-copper and brain-glucose values were inversely correlated (P = 0.021) in AD-patients but not controls. Abbreviations: CB, cerebellum; CG, cingulate gyrus; ENT, entorhinal cortex; HP, hippocampus; MCx, motor cortex; MTG, middle temporal gyrus; SCx, sensory cortex.
Figure 3 Regional brain glucose (upper panel) and brain copper (μmol/dry kg; lower panel) levels in patients with AD (n = 7–9/region; red) and controls (n = 7–9; black). Overall mean ( ± 95% CI; Confidence Interval) wet-weight/dry-weight ratio was 5.6 (5.4–5.8). Overall mean brain-glucose levels were higher (P = 9.7 × 10−13) and brain copper values lower (P = 1.6 × 10−8) in cases than controls. Mean brain copper in AD trended lower in every region: CB (P < 0.0001); MCx (P = 0.021); SCx (P = 0.027); CG (P = 0.0079); MTG (P = 0.013); ENT (P = 0.0046); and HP (P = 0.070); and there was modest evidence that overall brain-copper and brain-glucose values were inversely correlated (P = 0.021) in AD-patients but not controls. Abbreviations: CB, cerebellum; CG, cingulate gyrus; ENT, entorhinal cortex; HP, hippocampus; MCx, motor cortex; MTG, middle temporal gyrus; SCx, sensory cortex.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Cited by

See all 85

Metadata

Authors
Xu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., Lin, W., Herholz, K., Turner, C., Synek, B. J., Curtis, M. A., Rivers-Auty, J., Lawrence, C. B., Kellett, K. A. B., Hooper, N. M., Vardy, E. R. L. C., Wu, D., Unwin, R. D., Faull, R. L. M., Dowsey, A. W., & Cooper, G. J. S.
Affiliations
  • University of Auckland (NZ)
  • University of Manchester (GB)
  • Auckland City Hospital (NZ)
  • Salford Royal NHS Foundation Trust (GB)
  • Chinese Academy of Sciences (CN)
Corresponding author
Cooper, Garth J. S.
Venue
Scientific Reports
Published
2016-06-09
Volume
6
Issue
1
Pages
27524-27524
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2418667749
Cited by
85
References
88
Citations by year
2026: 3 · 2025: 5 · 2024: 9 · 2023: 10 · 2022: 10 · 2021: 11 · 2020: 15 · 2019: 9 · 2018: 4 · 2017: 6 · 2016: 3
FWCI
5.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion, cc-by)
  • ResearchSpace (University of Auckland) (submittedVersion, cc-by)
Funders
  • Tertiary Education Commission
  • Oakley Mental Health Research Foundation (3627092, 3456030, 3702870, 3701339, 3703253)
  • Maurice and Phyllis Paykel Trust (3627036)
  • Northwest Regional Development Agency
  • Maurice Wilkins Centre for Molecular Biodiscovery
  • Greater Manchester Comprehensive Local Research Network
  • Manchester Biomedical Research Centre
  • Medical Research Council (MR/L010445/1, MR/L023784/2, MR/L011093/2, MR/L011093/1, MR/L011093, MR/L011093/3, MR/L023784/1)
  • Health Research Council of New Zealand (3338701)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
Keywords
Alzheimer's disease, brain glucose metabolism, polyol pathway, sorbitol, fructose, copper regulation, neurodegeneration, dementia pathogenesis, plasma glucose, plasma copper
MeSH terms
Aged, Alzheimer Disease, Animals, Blood Glucose, Brain, Copper, Dementia, Female, Fructose, Glucose, Humans, Male, Metals, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Polymers, Probability, Sorbitol, Mass Spectrometry, Tissue Distribution, Case-Control Studies, Rats, Wistar, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer’s disease: metabolic basis for dementia. https://app.cochat.ai/papers/10.1038/srep27524
The paper
Xu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., Lin, W., Herholz, K., Turner, C., Synek, B. J., Curtis, M. A., Rivers-Auty, J., Lawrence, C. B., Kellett, K. A. B., Hooper, N. M., . . . Cooper, G. J. S. (2016). Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer’s disease: metabolic basis for dementia. Scientific Reports. https://doi.org/10.1038/srep27524

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.